QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
| |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification Number) |
Title of each Class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
|
|
|
|
☒ |
Accelerated filer |
☐ | |||
Non-accelerated filer |
☐ |
Smaller Reporting Company |
| |||
Emerging growth company |
|
Page No. |
||||||
Item 1. |
2 |
|||||
2 |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
6 |
||||||
7 |
||||||
Item 2. |
19 |
|||||
Item 3. |
27 |
|||||
Item 4. |
27 |
|||||
Item 1. |
28 |
|||||
Item 1A. |
28 |
|||||
Item 6. |
28 |
|||||
29 |
||||||
February 29, 2020 |
2019 |
|||||||
Unaudited |
Un udited a |
|||||||
Assets |
||||||||
Current Assets |
||||||||
Cash and cash equivalents |
$ | |
$ | |
||||
Marketable securities |
|
|
||||||
Accounts receivable, less allowance of $ |
|
|
||||||
Inventories |
|
|
||||||
Prepaid expenses and other current assets |
|
|
||||||
Total Current Assets |
|
|
||||||
Net Property and Equipment |
|
|
||||||
Other Assets |
||||||||
Goodwill |
|
|
||||||
Other non-amortizable intangible assets |
|
|
||||||
Amortizable intangible and other assets, net of accumulated amortization of $ |
|
|
||||||
Total Assets |
$ | |
$ | |
||||
Liabilities and Stockholders’ Equity |
||||||||
Current Liabilities |
||||||||
Accounts payable |
$ | |
$ | |
||||
Accrued compensation |
|
|
||||||
Income taxes |
|
|
||||||
Other accruals |
|
|
||||||
Total Current Liabilities |
|
|
||||||
Deferred Income Taxes |
|
|
||||||
Other Non-Current Liabilities |
|
|
||||||
Total Liabilities |
|
|
||||||
Commitments and Contingencies (note 8) |
||||||||
Equity |
||||||||
Preferred stock, $ |
|
— |
||||||
Common stock, $ |
|
|
||||||
Additional paid-in capital |
|
|
||||||
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
Retained earnings |
|
|
||||||
Total Stockholders’ Equity |
|
|
||||||
Total Liabilities and Stockholders’ Equity |
$ | |
$ | |
||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
February 29/28, |
February 29/28, |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
Revenues |
||||||||||||||||
Product revenues |
$ | |
$ | |
$ | |
$ | |
||||||||
Service revenues |
|
|
|
|
||||||||||||
Total Revenues |
|
|
|
|
||||||||||||
Cost of Revenues |
||||||||||||||||
Cost of product revenues |
|
|
|
|
||||||||||||
Cost of service revenues |
|
|
|
|
||||||||||||
Total Cost of Revenues |
|
|
|
|
||||||||||||
Gross Margin |
|
|
|
|
||||||||||||
Operating Expenses |
||||||||||||||||
Sales and marketing |
|
|
|
|
||||||||||||
General and administrative |
|
|
|
|
||||||||||||
Research and development |
|
|
|
|
||||||||||||
Total Operating Expenses |
|
|
|
|
||||||||||||
Operating Income |
|
|
|
|
||||||||||||
Other Income (Expense) |
||||||||||||||||
Interest income |
|
|
|
|
||||||||||||
Other income (expense) |
( |
) | |
( |
) | |
||||||||||
Total Other Income |
|
|
|
|
||||||||||||
Income Before Taxes |
|
|
|
|
||||||||||||
Provision for Income Taxes |
|
|
|
|
||||||||||||
Net Income |
$ | |
$ | |
$ | |
$ | |
||||||||
Net Income Per Share |
||||||||||||||||
Basic |
$ |
|
$ | |
$ |
|
$ | |
||||||||
Diluted |
$ |
|
$ | |
$ |
|
$ | |
||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
February 29/28, |
February 29/28, |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
Net income |
$ | |
$ | |
$ | |
$ | |
||||||||
Other comprehensive income (loss), net of tax: |
||||||||||||||||
currency translation adjustments |
( |
) | |
( |
) | |
||||||||||
Other comprehensive income, net of tax: |
||||||||||||||||
unrealized gain on marketable securities |
|
— |
|
— |
||||||||||||
Total comprehensive income |
$ | |
$ | |
$ | |
$ | |
||||||||
Accumulated |
||||||||||||||||||||||||
Additional |
Other |
|||||||||||||||||||||||
Common Stock |
Paid-in |
Comprehensive |
Retained |
|||||||||||||||||||||
Shares |
Amount |
Capital |
Income (Loss) |
Earnings |
Total |
|||||||||||||||||||
Balance at May 31, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
Net income for the three months ended August 31, 2019 |
— |
— |
— |
— |
|
|
||||||||||||||||||
Other comprehensive loss for the three months ended August 31 , 2019 |
— |
— |
— |
( |
) |
— |
( |
) | ||||||||||||||||
Balance at August 31, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
Net income for the three months ended November 30, 2019 |
— |
— |
— |
— |
|
|
||||||||||||||||||
Other comprehensive income for the three months ended November 30, 2019 |
— |
— |
— |
|
— |
|
||||||||||||||||||
Balance at November 30, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
Net income for the three months ended February 29, 2020 |
— |
— |
— |
— |
|
|
||||||||||||||||||
Other comprehensive loss for the three months ended February 29 , 2020 |
— |
— |
— |
( |
) |
— |
( |
) | ||||||||||||||||
Balance at February 29, 2020 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Accumulated |
||||||||||||||||||||||||
Additional |
Other |
|||||||||||||||||||||||
Common Stock |
Paid-in |
Comprehensive |
Retained |
|||||||||||||||||||||
Shares |
Amount |
Capital |
Income (Loss) |
Earnings |
Total |
|||||||||||||||||||
Balance at May 31, 2018 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
Net income for the three months ended August 31, 2018 |
— |
— |
— |
— |
|
|
||||||||||||||||||
Other comprehensive loss for the three months ended August 31, 2018 |
— |
— |
— |
( |
) | — |
( |
) | ||||||||||||||||
Balance at August 31, 2018 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
Net income for the three months ended November 30, 2018 |
— |
— |
— |
— |
|
|
||||||||||||||||||
Other comprehensive income for the three months ended November 30, 2018 |
— |
— |
— |
|
— |
|
||||||||||||||||||
Balance at November 30, 2018 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
Shares repurchased |
( |
) | ( |
) | ( |
) | — |
— |
( |
) | ||||||||||||||
Net income for the three months ended February 28, 2019 |
— |
— |
— |
— |
|
|
||||||||||||||||||
Other comprehensive loss for the three months ended February 28, 2019 |
— |
— |
— |
|
— |
|
||||||||||||||||||
Balance at February 28, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
Nine Months Ended February 29/28, |
||||||||
2020 |
2019 |
|||||||
Cash Flows From Operating Activities |
||||||||
Net Income |
$ | |
$ | |
||||
Adjustments to reconcile net income to net cash from operating activities: |
||||||||
Depreciation and amortization |
|
|
||||||
Share-based compensation |
|
|
||||||
Change in operating assets and liabilities, net of business acquisitions: |
||||||||
Accounts receivable |
|
( |
) | |||||
Inventories |
( |
) | ( |
) | ||||
Prepaid expenses and other current assets |
( |
) | ( |
) | ||||
Accounts payable, accruals and other changes |
|
( |
) | |||||
Net Cash From Operating Activities |
|
|
||||||
Cash Flows For Investing Activities |
||||||||
Purchases of property, equipment and other assets |
( |
) | ( |
) | ||||
Proceeds from the sale of marketable securities |
|
|
||||||
Purchases of marketable securities |
( |
) | ( |
) | ||||
Business acquisitions, net of cash acquired |
( |
) | ( |
) | ||||
Net Cash For Investing Activities |
( |
) | ( |
) | ||||
Cash Flows From Financing Activities |
||||||||
Exercise of stock options and issuance of employee stock purchase plan shares |
|
|
||||||
Repurchase of common stock |
— |
( |
) | |||||
Net Cash From Financing Activities |
|
|
||||||
Effect of Exchange Rates on Cash |
( |
) | |
|||||
Net Increase In Cash and Cash Equivalents |
|
|
||||||
Cash and Cash Equivalents, Beginning of Period |
|
|
||||||
Cash and Cash Equivalents, End of Period |
$ | |
$ | |
||||
• | We elected the package of practical expedients available for transition that allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. |
• | We did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset. |
• | For all asset classes, we elected to not recognize a right-of-use asset and lease liability for short-term leases. |
• | For all asset classes, we elected to not separate non-lease components from lease components to which they relate and have accounted for the combined lease and non-lease components as a single lease component. |
• | The determination of the discount rate used in a lease is our incremental borrowing rate that is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. |
February 29, 2020 |
||||
(in thousands) |
||||
Right of use - assets |
$ | |
||
Lease liabilities - current |
|
|||
Lease liabilities - non-current |
|
February 29, 2020 |
||||
Weighted average remaining lease term |
|
|||
Weighted average discount rate |
|
Three Months Ended February 29, 2020 |
Nine Months Ended February 29, 2020 |
|||||||
(in thousands) |
(in thousands) |
|||||||
Operating leases |
$ | |
$ | |
||||
Short term leases |
|
|
||||||
Total lease expense |
$ | |
$ | |
||||
Amount |
||||
(in thousands) |
||||
Years ending May 31, |
||||
2020 (1) |
$ |
|
||
2021 |
|
|||
2022 |
|
|||
2023 |
|
|||
2024 |
|
|||
2025 and thereafter |
|
|||
Total lease payments |
|
|||
Less: imputed interest |
|
|||
Total lease liabilities |
$ | |
||
(1) | Excluding the nine months ended February 29, 2020. |
Future Minimum Lease Payments |
||||
(in thousands) |
||||
Years ending May 31, |
||||
2020 |
$ |
|
||
2021 |
|
|||
2022 |
|
|||
2023 |
|
|||
Thereafter |
|
|||
$ |
|
|||
• | Identification of the contract with a customer; |
• | Identification of the performance obligations in the contract; |
• | Determination of the transaction price; |
• | Allocation of the transaction price to the performance obligations in the contract; and |
• | Recognition of revenue when, or as, the Company satisfies the performance obligations. |
• | Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; |
• | Consumable products marketed to veterinarians and animal health product distributors; and |
• | Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities. |
• | Genomic identification and related interpretive bioinformatic services; and |
• | Other commercial laboratory services. |
Three Months ended February 2 9 /28 , |
Nine Months ended February 2 9 /28 , |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
(in thousands) |
||||||||||||||||
Food Safety |
||||||||||||||||
Natural Toxins, Allergens & Drug Residues |
$ | |
$ | |
$ | |
$ | |
||||||||
Bacterial & General Sanitation |
|
|
|
|
||||||||||||
Culture Media & Other |
|
|
|
|
||||||||||||
Rodenticides, Insecticides & Disinfectants |
|
|
|
|
||||||||||||
Genomics Services |
|
|
|
|
||||||||||||
$ | |
$ | |
$ | |
$ | |
|||||||||
Animal Safety |
||||||||||||||||
Life Sciences |
$ | |
$ | |
$ | |
$ | |
||||||||
Veterinary Instruments & Disposables |
|
|
|
|
||||||||||||
Animal Care & Other |
|
|
|
|
||||||||||||
Rodenticides, Insecticides & Disinfectants |
|
|
|
|
||||||||||||
Genomics Services |
|
|
|
|
||||||||||||
$ | |
$ | |
$ | |
$ | |
|||||||||
Total Revenues |
$ | 99,869 |
$ | |
$ | 309,096 |
$ | |
||||||||
February 29, |
May 31, |
|||||||
2020 |
2019 |
|||||||
(in thousands) |
||||||||
Raw materials |
$ | |
$ | |
||||
Work-in-process |
|
|
||||||
Finished and purchased goods |
|
|
||||||
$ | |
$ | |
|||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
February 29/28, |
February 29/28, |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
(in thousands, except per share amounts) |
||||||||||||||||
Numerator for basic and diluted net income per share: |
||||||||||||||||
Net income attributable to Neogen |
$ | |
$ | |
$ |
|
$ | |
||||||||
Denominator for basic net income per share: |
||||||||||||||||
Weighted average shares |
|
|
|
|
||||||||||||
Effect of dilutive stock options |
|
|
|
|
||||||||||||
Denominator for diluted net income per share |
|
|
|
|
||||||||||||
Net income attributable to Neogen per share: |
||||||||||||||||
Basic |
$ | |
$ | |
$ | |
$ | |
||||||||
Diluted |
$ | |
$ | |
$ | |
$ | |
||||||||
|
Food Safety |
Animal Safety |
Corporate and Eliminations (1) |
Total |
||||||||||||
(in thousands) |
||||||||||||||||
As of and for the three months ended February 29, 2020 |
||||||||||||||||
Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
Service revenues to external customers |
|
|
— |
|
||||||||||||
Total revenues to external customers |
|
|
— |
|
||||||||||||
Operating income (loss) |
|
|
( |
) | |
|||||||||||
Total assets |
|
|
|
|
||||||||||||
As of and for the three months ended February 28, 2019 |
||||||||||||||||
Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
Service revenues to external customers |
|
|
— |
|
||||||||||||
Total revenues to external customers |
|
|
— |
|
||||||||||||
Operating income (loss) |
|
|
( |
) | |
|||||||||||
Total assets |
|
|
|
|
(1) | Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities , current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions. |
|
Food Safety |
Animal Safety |
Corporate and Eliminations (1) |
Total |
||||||||||||
(in thousands) |
||||||||||||||||
As of and for the nine months ended February 29, 2020 |
||||||||||||||||
Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
Service revenues to external customers |
|
|
— |
|
||||||||||||
Total revenues to external customers |
|
|
— |
|
||||||||||||
Operating income (loss) |
|
|
( |
) | |
|||||||||||
As of and for the nine months ended February 28, 2019 |
||||||||||||||||
Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
Service revenues to external customers |
|
|
— |
|
||||||||||||
Total revenues to external customers |
|
|
— |
|
||||||||||||
Operating income (loss) |
|
|
( |
) | |
(1) | Includes elimination of intersegment transactions. |
Three months ended |
Nine months ended |
|||||||||||||||
February 29/28, |
February 29/28, |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
(in thousands) |
(in thousands) |
|||||||||||||||
Revenues by Geographic Location |
||||||||||||||||
Domestic |
$ | |
$ | |
$ | |
$ | |
||||||||
International |
|
|
|
|
||||||||||||
Total revenue |
|
|
|
|
||||||||||||
Weighted- |
||||||||
Average |
||||||||
(Options in thousands) |
Shares |
Exercise Price |
||||||
Options outstanding June 1, 2019 |
|
$ | |
|||||
Granted |
|
|
||||||
Exercised |
( |
) | |
|||||
Forfeited |
( |
) | |
|||||
Options outstanding February 29, 2020 |
|
$ | |
FY 2020 |
||||
Risk-free interest rate |
|
|||
Expected dividend yield |
|
|||
Expected stock price volatility |
|
|||
Expected option life |
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
• | Consolidated revenues were $99.9 million in the third quarter of fiscal 2020, an increase of 2% compared to $97.7 million in the third quarter of fiscal 2019. Organic sales growth in the third quarter of fiscal 2020 was 1%. For the year to date period, consolidated revenues were $309.1 million, an increase of 2% compared to $304.4 million in the same period in the prior fiscal year. Organic sales rose 1% for the nine month period. |
• | Food Safety segment sales were $50.5 million in the third quarter of the current fiscal year, a decline of 1% compared to $51.1 million in the same period of the prior year. Organic sales declined 3% during the quarter; contributions from four acquisitions executed during the quarter totaled $990,000. For the year to date, Food Safety segment sales were $158.4 million, an increase of 1% compared to $157.0 million in the same period of the prior fiscal year; excluding acquisitions, sales were flat. |
• | Animal Safety segment sales were $49.4 million in the third quarter of fiscal 2020, an increase of 6% compared to $46.6 million in the third quarter of fiscal 2019. Organic sales in this segment also rose 6% in the third quarter, with only a minor contribution from the January 1, 2019 acquisition of Delta Genomics. For the year to date, Animal Safety segment sales were $150.7 million, an increase of 2% compared to $147.4 million in the same period a year ago. Year to date organic sales also increased 2%. |
• | International sales in the third quarter of fiscal 2020 were 40% of total sales compared to 41% of total sales in the third quarter of fiscal 2019. For each year to date period presented, international sales were 40% of total sales. |
• | Our effective tax rate in the third quarter was 14.4% compared to 21.4% in the prior year third quarter; the fiscal 2020 year to date effective tax rate was 15.6% compared to 17.0% for the same period a year ago. |
• | Net income for the quarter ended February 29, 2020 was $12.2 million, or $0.23 per diluted share, a decrease of 7% compared to $13.1 million, or $0.25 per share in the same period in the prior year. For the year to date, net income was $43.1 million, or $0.82 per share, a decrease of 3% compared to prior year to date net income of $44.4 million, or $0.85 per diluted share. |
• | Cash provided from operating activities in the first nine months of fiscal 2020 was $60.3 million, compared to $43.0 million in the same period of fiscal 2019. |
Three Months Ended February 29, 2020 |
Nine Months Ended February 29, 2020 |
|||||||||||||||
Revenue |
Revenue |
Revenue |
Revenue |
|||||||||||||
% Increase/(Decrease) USD |
% Increase/(Decrease) Local Currency |
% Increase USD |
% Increase Local Currency |
|||||||||||||
UK Companies |
5 |
% | 4 |
% | 3 |
% | 5 |
% | ||||||||
Brazilian Companies |
(16 |
)% | (6 |
)% | (5 |
)% | 1 |
% | ||||||||
Neogen Latinoamerica |
15 |
% | 11 |
% | 8 |
% | 7 |
% | ||||||||
Neogen China |
37 |
% | 41 |
% | 20 |
% | 24 |
% | ||||||||
Neogen India |
18 |
% | 19 |
% | 11 |
% | 11 |
% | ||||||||
Neogen Canada |
75 |
% | 73 |
% | 135 |
% | 135 |
% | ||||||||
Neogen Australasia |
7 |
% | 12 |
% | 15 |
% | 22 |
% |
Three Months Ended February 29/28, |
||||||||||||||||
2020 |
2019 |
Increase/ (Decrease) |
% |
|||||||||||||
(in thousands) |
||||||||||||||||
Food Safety |
||||||||||||||||
Natural Toxins, Allergens & Drug Residues |
$ | 17,154 |
$ | 18,612 |
$ | (1,458 |
) | (8 |
)% | |||||||
Bacterial & General Sanitation |
9,413 |
9,519 |
(106 |
) | (1 |
)% | ||||||||||
Culture Media & Other |
11,222 |
11,893 |
(671 |
) | (6 |
)% | ||||||||||
Rodenticides, Insecticides & Disinfectants |
7,964 |
5,953 |
2,011 |
34 |
% | |||||||||||
Genomics Services |
4,745 |
5,136 |
(391 |
) | (8 |
)% | ||||||||||
$ | 50,498 |
$ | 51,113 |
$ | (615 |
) | (1 |
)% | ||||||||
Animal Safety |
||||||||||||||||
Life Sciences |
$ | 1,376 |
$ | 1,823 |
$ | (447 |
) | (25 |
)% | |||||||
Veterinary Instruments & Disposables |
10,799 |
10,682 |
117 |
1 |
% | |||||||||||
Animal Care & Other |
6,667 |
6,554 |
113 |
2 |
% | |||||||||||
Rodenticides, Insecticides & Disinfectants |
14,558 |
13,525 |
1,033 |
8 |
% | |||||||||||
Genomics Services |
15,971 |
14,003 |
1,968 |
14 |
% | |||||||||||
$ | 49,371 |
$ | 46,587 |
$ | 2,784 |
6 |
% | |||||||||
Total Revenues |
$ | 99,869 |
$ | 97,700 |
$ | 2,169 |
2 |
% | ||||||||
Nine Months Ended February 29/28, |
||||||||||||||||
2020 |
2019 |
Increase/ (Decrease) |
% |
|||||||||||||
(in thousands) |
||||||||||||||||
Food Safety |
||||||||||||||||
Natural Toxins, Allergens & Drug Residues |
$ | 57,950 |
$ | 58,021 |
$ | (71 |
) | 0 |
% | |||||||
Bacterial & General Sanitation |
31,345 |
30,807 |
538 |
2 |
% | |||||||||||
Culture Media & Other |
35,259 |
36,302 |
(1,043 |
) | (3 |
)% | ||||||||||
Rodenticides, Insecticides & Disinfectants |
20,859 |
18,521 |
2,338 |
13 |
% | |||||||||||
Genomics Services |
12,961 |
13,395 |
(434 |
) | (3 |
)% | ||||||||||
$ | 158,374 |
$ | 157,046 |
$ | 1,328 |
1 |
% | |||||||||
Animal Safety |
||||||||||||||||
Life Sciences |
$ | 4,901 |
$ | 5,794 |
$ | (893 |
) | (15 |
)% | |||||||
Veterinary Instruments & Disposables |
32,621 |
32,769 |
(148 |
) | 0 |
% | ||||||||||
Animal Care & Other |
20,859 |
21,900 |
(1,041 |
) | (5 |
)% | ||||||||||
Rodenticides, Insecticides & Disinfectants |
47,462 |
49,460 |
(1,998 |
) | (4 |
)% | ||||||||||
Genomics Services |
44,879 |
37,455 |
7,424 |
20 |
% | |||||||||||
$ | 150,722 |
$ | 147,378 |
$ | 3,344 |
2 |
% | |||||||||
Total Revenues |
$ | 309,096 |
$ | 304,424 |
$ | 4,672 |
2 |
% | ||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
February 29/28 |
February 29/28 |
|||||||||||||||
(dollars in thousands) |
2020 |
2019 |
2020 |
2019 |
||||||||||||
Interest income (net of expense) |
$ | 1,600 |
$ | 1,335 |
$ | 4,381 |
$ | 3,290 |
||||||||
Foreign currency transactions |
(420 |
) | 104 |
(889 |
) | (354 |
) | |||||||||
Royalty income |
— |
— |
1 |
60 |
||||||||||||
Deoxi contingent consideration |
— |
— |
— |
(9 |
) | |||||||||||
Quat-Chem contingent consideration |
— |
— |
— |
422 |
||||||||||||
Other |
28 |
545 |
56 |
688 |
||||||||||||
Total Other Income |
$ | 1,208 |
$ | 1,984 |
$ | 3,549 |
$ | 4,097 |
||||||||
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
Evaluation |
of Disclosure Controls and Procedures |
Item 1. |
Legal Proceedings |
Item 1A. |
Risk Factors |
Item 6. |
Exhibits |
3 |
||||
10 |
||||
31.1 |
||||
31.2 |
||||
32 |
||||
101.INS |
Inline XBRL Instance Document | |||
101.SCH |
Inline XBRL Taxonomy Extension Schema Document | |||
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||
101.DEF |
Inline XBRL Taxonomy Extension Definition Document | |||
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document | |||
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||
EX-104 |
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
NEOGEN CORPORATION | ||||||
(Registrant) | ||||||
Dated: April 3, 2020 |
||||||
/s/ John E. Adent | ||||||
John E. Adent | ||||||
President & Chief Executive Officer | ||||||
(Principal Executive Officer) | ||||||
Dated: April 3, 2020 |
||||||
/s/ Steven J. Quinlan | ||||||
Steven J. Quinlan | ||||||
Vice President & Chief Financial Officer | ||||||
(Principal Financial Officer and Principal Accounting Officer) |
13a. CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
NEOGEN CORPORATION AND SUBSIDIARIES
CEO CERTIFICATION
I, John E. Adent, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended February 29, 2020 of Neogen Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and |
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting. |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of registrants board of directors: |
a) | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: April 3, 2020
/s/ John E. Adent |
John E. Adent |
President & Chief Executive Officer |
(Principal Executive Officer) |
13a. CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
NEOGEN CORPORATION AND SUBSIDIARIES
CFO CERTIFICATION
I, Steven J. Quinlan, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended February 29, 2020 of Neogen Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and |
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting. |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of registrants board of directors: |
a) | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: April 3, 2020
/s/ Steven J. Quinlan |
Steven J. Quinlan |
Vice President & Chief Financial Officer |
(Principal Financial Officer and Principal Accounting Officer) |
18 U.S.C. SECTION 1350 CERTIFICATION
NEOGEN CORPORATION
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q of Neogen Corporation (the Company) for the period ended February 29, 2020 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, John E. Adent, as Chief Executive Officer of the Company and I, Steven J. Quinlan, as Chief Financial Officer, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | This Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | Information contained in this Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Dated: April 3, 2020
/s/ John E. Adent |
John E. Adent |
President & Chief Executive Officer |
(Principal Executive Officer) |
/s/ Steven J. Quinlan |
Steven J. Quinlan |
Vice President & Chief Financial Officer |
(Principal Financial Officer and Principal Accounting Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Future Minimum Lease Payments (Detail) $ in Thousands |
May 31, 2019
USD ($)
|
---|---|
2020 | $ 1,112 |
2021 | 810 |
2022 | 297 |
2023 | 101 |
Thereafter | 0 |
Total lease payments | $ 2,320 |
Accounting Policies |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb. 29, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies | 1. ACCOUNTING POLICIES BASIS OF PRESENTATION AND CONSOLIDATION The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and nine month periods ended February 29, 2020 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2020. For more complete financial information, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2019.Recently Adopted Accounting Standards Leases On June 1, 2019, the Company adopted ASU No. 2016-02— Leases. Refer to Leases section of Note 1 for further information.Recent Accounting Pronouncements Not Yet Adopted Financial Instruments - Credit Losses In June 2016, the FASB issued ASU No. 2016-13—Measurement of Credit Losses on Financial Instruments, which changes how companies measure credit losses on most financial instruments measured at amortized cost and certain other instruments, such as loans, receivables and held-to-maturity debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 is effective for fiscal periods beginning after December 15, 2019 and must be adopted as a cumulative effect adjustment to retained earnings. The Company does not believe adoption of this guidance will have a material impact on its consolidated financial statements.Fair Value Measurements In August 2018, the FASB issued ASU 2018-13—Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements of fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. The Company does not believe adoption of this guidance will have an impact on its consolidated financial statements.Cloud Computing Implementation Cost In August 2018, the FASB issued ASU 2018-15—Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Cost Incurred in a Cloud Computing Arrangement That Is a Service Contract, which clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019. The Company does not believe adoption of this guidance will have an impact on its consolidated financial statements.Comprehensive Income Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on marketable securities. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments. Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Cash and Cash Equivalents Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Marketable Securities The Company has marketable securities held by banks or broker-dealers at February 29, 2020, consisting of short-term domestic certificates of deposit, and commercial paper and U.S. treasuries rated at least A-1/P-1 (short-term) and A/A2 (long-term) with maturities between 91 days and two years. These securities are classified as available for sale. The primary objective of the Company’s investment activity is to preserve capital for the purpose of funding operations, capital expenditures and business acquisitions; investments are not entered into for trading or speculative purposes. These securities are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the consolidated statements of income.ESTIMATES AND ASSUMPTIONS The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes to the critical accounting policies and estimates disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2019.There were no significant changes to the contractual obligations or contingent liabilities and commitments disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2019.Accounts Receivable Allowance Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, that amount is charged against the allowance for doubtful accounts. Inventory The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations. Goodwill and Other Intangible Assets Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants not-to-compete and patents. Customer-based intangibles are amortized on either an accelerated or straight-line basis, reflecting the pattern in which the economic benefits are consumed, while all other amortizable intangibles are amortized on a straight-line basis; intangibles are generally amortized over 5 to 25 years. We review the carrying amounts of goodwill and other non-amortizable intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired by performing a quantitative assessment. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is recorded to operations.Long-Lived Assets Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations. Equity Compensation Plans Share options awarded to employees and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. To value options, several recognized valuation models exist. None of these models can be singled out as being the best or most correct. The model applied by us can handle most of the specific features included in the options granted, which is the reason for its use. If a different model were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 5. Income Taxes We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year. Leases In February 2016, the FASB issued ASU No. 2016-02—Leases, to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessor have not significantly changed from previous U.S. GAAP. This ASU was effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018. We adopted this ASU on June 1, 2019; the impact on our consolidated financial statements was immaterial.We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all our leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term. Our lease terms may include options to extend when it is reasonably certain that we will exercise that option. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease. With the adoption of ASC 842 on June 1, 2019, we recognized all leases with terms greater than 12 months in duration on our consolidated balance sheets as right-of-use assets and lease liabilities of approximately $2.0 million each as of June 1, 2019. We adopted the standard using the prospective approach and did not retrospectively apply to prior periods. Right-of-use assets are recorded in other assets on our consolidated balance sheets. Current and non-current lease liabilities are recorded in other accruals within current liabilities and other non-current liabilities, respectively, on our consolidated balance sheets.We have made certain assumptions and judgments when applying ASC 842, the most significant of which are:
Supplemental balance sheet information related to operating leases was as follows:
The weighted average remaining lease term and weighted average discount rate were as follows:
Operating lease expenses are classified as cost of revenues or operating expenses on the consolidated statements of income. The components of lease expense were as follows:
Cash paid for amounts included in the measurement of lease liabilities for operating leases included in cash flows from operations on the statement of cash flows were approximately $868,000 for the nine months ended February 29, 2020. There were no non-cash additions to right-of-use assets obtained from new operating lease liabilities for the nine months ended February 29, 2020.Undiscounted minimum lease payments as of February 29, 2020 were as follows:
The aggregate amount of future minimum annual rental payments applicable to noncancelable leases as of May 31, 2019 were as follows:
Revenue Recognition The Company determines the amount of revenue to be recognized through application of the following steps:
Essentially all our revenue is generated through contracts with our customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met. In certain situations, we provide rebates, marketing support, credits or incentives to selected customers, which are accounted for as variable consideration when estimating the amount of revenue to recognize on a contract. Variable consideration reduces the amount of revenue that is recognized. These variable consideration estimates are updated at the end of each reporting period based on information currently available. The performance obligations in our contracts are generally satisfied well within one year of the contract inception. In such cases, we have elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. We have elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. The Company accounts for shipping and handling for products as a fulfillment activity when goods are shipped. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. The Company’s terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred. We derive revenue from two primary sources - product revenue and service revenue. Product revenue consists of shipments of:
Revenues for our products are recognized and invoiced when the product is shipped to the customer. Service revenue consists primarily of:
Revenues for our genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer. Payment terms for products and services are generally 30 to 60 days; international terms may be longer. The following table presents disaggregated revenue by major product and service categories for the three and nine month periods ended February 29, 2020 and February 28, 2019:
|
Supplemental Balance Sheet Information Related to Operating Leases (Detail) - USD ($) $ in Thousands |
Feb. 29, 2020 |
Jun. 01, 2019 |
---|---|---|
Right of use - assets | $ 1,755 | $ 2,000 |
Lease liabilities - current | 325 | |
Lease liabilities - non-current | $ 1,467 |
Net Income per Share (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb. 29, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculation of Net Income Per Share | The calculation of net income per share follows:
|
Consolidated Statements of Income - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Feb. 29, 2020 |
Feb. 28, 2019 |
Feb. 29, 2020 |
Feb. 28, 2019 |
|
Revenues | ||||
Total Revenues | $ 99,869 | $ 97,700 | $ 309,096 | $ 304,424 |
Cost of Revenues | ||||
Total Cost of Revenues | 54,539 | 53,072 | 164,546 | 163,034 |
Gross Margin | 45,330 | 44,628 | 144,550 | 141,390 |
Operating Expenses | ||||
Sales and marketing | 17,675 | 16,722 | 53,206 | 52,454 |
General and administrative | 10,789 | 10,018 | 32,473 | 30,337 |
Research and development | 3,823 | 3,249 | 11,292 | 9,235 |
Total Operating Expenses | 32,287 | 29,989 | 96,971 | 92,026 |
Operating Income | 13,043 | 14,639 | 47,579 | 49,364 |
Other Income (Expense) | ||||
Interest income | 1,600 | 1,335 | 4,381 | 3,290 |
Other income (expense) | (393) | 649 | (832) | 807 |
Total Other Income | 1,207 | 1,984 | 3,549 | 4,097 |
Income Before Taxes | 14,250 | 16,623 | 51,128 | 53,461 |
Provision for Income Taxes | 2,050 | 3,550 | 8,000 | 9,100 |
Net Income | $ 12,200 | $ 13,073 | $ 43,128 | $ 44,361 |
Net Income Per Share | ||||
Basic | $ 0.23 | $ 0.25 | $ 0.82 | $ 0.86 |
Diluted | $ 0.23 | $ 0.25 | $ 0.82 | $ 0.85 |
Product Revenues | ||||
Revenues | ||||
Total Revenues | $ 77,736 | $ 77,375 | $ 247,071 | $ 249,897 |
Cost of Revenues | ||||
Total Cost of Revenues | 41,068 | 41,902 | 128,658 | 132,157 |
Service Revenues | ||||
Revenues | ||||
Total Revenues | 22,133 | 20,325 | 62,025 | 54,527 |
Cost of Revenues | ||||
Total Cost of Revenues | $ 13,471 | $ 11,170 | $ 35,888 | $ 30,877 |
Stock Purchase - Additional Information (Detail) - USD ($) |
1 Months Ended | |
---|---|---|
Dec. 31, 2018 |
Oct. 31, 2018 |
|
Stock Repurchase Program [Line Items] | ||
Shares authorized to purchase | 3,000,000 | |
Cost of repurchased shares, including commissions | $ 3,134,727 | |
Number of shares repurchased | 50,000 |
L"[=?QF^;=P[Y)IJ_14)= <=)5MOO]GWGG_E1$' 2'&WT515+'R-P)NSH%OD58"""1UU*+*D
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M[--OH%!1TJ< 1IJ[+2[= <7^OV&7K^EU[3P>]C,>JJ$V/^9ON
MQY;6.NQ13IO;VOWI:\;P9 +DY_[3>
M!]KTDY,:":0(L$ F[>6M-P-KHM]LO'JM?0 8 AC'T_>3#_;%@^?_.G^O3FG
M#9Q\ZCO?Y4DAR8TPEK\5T7$_]>!,L*6/#(Z'>!@_/0P@C/"XWHM1IJD-W1\R
M]Y]'9O2>K8O+18 IH,56P$ GR#5>1.Q@TC(TL02T:%OLS!0F/2=' 3?$\4V//C"[=VZM[6
M0Q0"%QXMF;CG/&$,7MS"$D_+:+(55Z2+HOFV"AJ;<>]3H=YAXH*\Q 1U>&\%[03R4?4CQB
MX;AT1R@3D4C$EXO4YQ=_46^C?EJGM!W\:,OC##R#>?6>Z)Z
M9^@XQ'^D(S^DO?.CQVL2V%9$7HS/E>]9D1E>^C?$_VF;1%C4,%6_IK,<*%N\
M]AX&!^HJ(W(_&R8U^[;A4 G\25QJ@2F)73M>'+@1?8TQ;:\A-L,0 :G%(_4T
MA7=,(_V.F(FYU7HHAX"-)GP^'EZ(SP]>4HV1>EY)E?
MJT3&A1UC)%X:;?=!JC'L-R?BYLI
7P+J,P" V7J=BT$[W$J7O74>7!8/4D
ML(PTKLE18% ].'&PEEHG 5I%YPZ*4<:O+^O:*R?<0$%!04%!';*"$J4HH::J
M
2F^3C]_SVW\EC[[W'&M?E!K2R&>!UF^A9[8^W3([
MR])VIRPZH[3^<&*D4#I/5;SK[;9%%<%3?S 8M-MW_59FW; =_1;&.XF[JU >
M21>XQ$51-1=GEW^>74BGE]=7E]?#V_/+"VEX\46Z^?'YYOS+^?#Z_.PFQ2BD
M4!4R*T]FE[=4*K>7TOG%[=GU^7/\'XK=\.V7Z*$"==9HX"*_L[O0D5,K_,4WY__?A7KQI=@<
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M%U.]J67(-UV@K,/,X'TYO)F2 "$MG*T!S7SBA/.'//W@8/GDP'F%^&.'-XAJ7Q
MJ+,!?3*D1VF%Z6?E/EMX4[>"QJ'-B^#*(!50)=Y@ K0T2SQU%BOAA.J07R(:D8S)B/
MA!0T0'4*$XEEH@$^PSD.?:%=C9>22T9(HOF*^RF@+40F$&8RRNSTA60$80J:
M4@6!P9A*[!N#8I1H<,JO/3/!*,0\ 4_])@3RX[NKVP^7VC1T EG;'H&<*1U$
M5+33,\N7^1&@PL1YBC"E**XQ2L]0)'TJ"RV3OX#P'2=^+"M"MM(.BS?LVO\
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M++^86+N"UE'>J))'DV
]%A/3=2_Z+/3I>2W.>((W%8PB7@@&\%X8TKD(H_4/J*&MGGGPF%I
M6[ PT"9^@9ZM@VQ/GD;2^K5"1S:C@P/>%*+K,T?\)3[?0M0\AD\P!2_Z%(XA
M\5WX#3" >[Y0US%5TD)KQY_"<:BY)HP,1T_@/=IH#>#SL)4N6B66P&D=#0SF
MP^DBAW- 2!PA&NK @=,'+ ^!^A39//'GR-]/Z%HQ='T/AWDX%0P1HZ7T;T@-
M_!YS-L#R JA3" =P-@58FS#3"2:QY@1:0^#;PS#P4+VGV.;)/T=81UA7,:S[
M[HF,6@O6CAJDS<$ 1]^ZJQS^0!:\FR7^+@(;'.V<3.:&C!?X8B 80SXAGX;Q
ML(R!C!8 3 I6ULP[WY8*JNGH:?U3^(;PB]+K/8;M=*1O@Y#SM)^C8.D.-P"E
MRU/$$F/GII^YVR8E'9#/0G\XNC>5?UKH,3:/?)Q10E<2W#Q5!]!-UA.6.("D
M(PUF0-X?.K/W